Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review
- PMID: 34082807
- PMCID: PMC8173883
- DOI: 10.1186/s13023-021-01884-4
Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review
Abstract
Background: Progressive familial intrahepatic cholestasis is a rare, heterogeneous group of liver disorders of autosomal recessive inheritance, characterised by an early onset of cholestasis with pruritus and malabsorption, which rapidly progresses, eventually culminating in liver failure. For children and their parents, PFIC is an extremely distressing disease. Significant pruritus can lead to severe cutaneous mutilation and may affect many activities of daily living through loss of sleep, irritability, poor attention, and impaired school performance.
Methods: Databases including MEDLINE and Embase were searched for publications on PFIC prevalence, incidence or natural history, and the economic burden or health-related quality of life of patients with PFIC. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed.
Results: Three systematic reviews and twenty-two studies were eligible for inclusion for the epidemiology of PFIC including a total of 2603 patients. Study periods ranged from 3 to 33 years. Local population prevalence of PFIC was reported in three studies, ranging from 9.0 to 12.0% of children admitted with cholestasis, acute liver failure, or splenomegaly. The most detailed data come from the NAPPED study where native liver survival of >15 years is predicted in PFIC2 patients with a serum bile acid concentration below 102 µmol/L following bile diversion surgery. Burden of disease was mainly reported through health-related quality of life (HRQL), rates of surgery and survival. Rates of biliary diversion and liver transplant varied widely depending on study period, sample size and PFIC type, with many patients have multiple surgeries and progressing to liver transplant. This renders data unsuitable for comparison.
Conclusion: Using robust and transparent methods, this systematic review summarises our current knowledge of PFIC. The epidemiological overview is highly mixed and dependent on presentation and PFIC subtype. Only two studies reported HRQL and mortality results were variable across different subtypes. Lack of data and extensive heterogeneity severely limit understanding across this disease area, particularly variation around and within subtypes.
Keywords: ABCB11; ABCB4; ATP8B1; Bile acid; NR1H4 and Myo5b; Pruritus; TJP2.
Conflict of interest statement
Funding was received from Albireo Pharma, Inc. for medical writing purposes.
Figures


Similar articles
-
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Gastroenterol Hepatol. 2024 Jul;9(7):620-631. doi: 10.1016/S2468-1253(24)00080-3. Epub 2024 May 6. Lancet Gastroenterol Hepatol. 2024. PMID: 38723644 Clinical Trial.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Immunohistochemistry in Progressive Familial Intrahepatic Cholestasis (PFIC): Bridging Gap Between Morphology and Genetics.J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102562. doi: 10.1016/j.jceh.2025.102562. Epub 2025 Mar 28. J Clin Exp Hepatol. 2025. PMID: 40384941
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047
-
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240. Health Technol Assess. 2006. PMID: 16796930
Cited by
-
Long-Term Results of Pediatric Liver Transplantation for Progressive Familial Intrahepatic Cholestasis.J Clin Med. 2022 Aug 11;11(16):4684. doi: 10.3390/jcm11164684. J Clin Med. 2022. PMID: 36012923 Free PMC article.
-
Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis.JHEP Rep. 2023 Oct 27;6(1):100949. doi: 10.1016/j.jhepr.2023.100949. eCollection 2024 Jan. JHEP Rep. 2023. PMID: 38192535 Free PMC article.
-
Surgical versus Medical Management of Progressive Familial Intrahepatic Cholestasis-Case Compilation and Review of the Literature.Children (Basel). 2023 May 26;10(6):949. doi: 10.3390/children10060949. Children (Basel). 2023. PMID: 37371180 Free PMC article. Review.
-
San-Huang-Chai-Zhu Formula Ameliorates Liver Injury in Intrahepatic Cholestasis through Suppressing SIRT1/PGC-1α-Regulated Mitochondrial Oxidative Stress.Evid Based Complement Alternat Med. 2022 Jul 8;2022:7832540. doi: 10.1155/2022/7832540. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35845569 Free PMC article.
-
A family with gallstone disease: defining inherited risk in the era of clinical genetic testing.Intern Emerg Med. 2025 Mar;20(2):509-514. doi: 10.1007/s11739-024-03854-7. Epub 2025 Jan 9. Intern Emerg Med. 2025. PMID: 39786488
References
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources